As part of the deal, Neurotrope will pay WCT about $300,000 for the services and related third-party costs. In early second quarter of 2015, Neurotrope plans to submit
FOLFIRI is an irinotecan-based chemotherapy regimen, which is frequently used in first-line colorectal cancer treatment in Europe. The approval from the new indication is based on data from
The deal will give BMS exclusive access to uniQure’s gene therapy technology platform for the development of new treatments. The companies will collaborate on up to ten targets,
Demcizumab is a humanized monoclonal antibody that inhibits Delta-Like Ligand 4 (DLL4) in the Notch signaling pathway. Under the deal, OncoMed’s demcizumab will be tested in combination with
BIND is focused on developing targeted and programmable therapeutics called Accurins. The deal was originally established in April 2013 and the timeline for Pfizer to exercise its option
Under the deal, Schrödinger could receive up to $120m, which includes preclinical milestones. Computer aided design (CAD) plays a major role in nearly all industries ranging from airplane
Nucynta is indicated to manage moderate-to-severe acute pain in adults, Nucynta ER extended release tablets are indicated to manage pain, including neuropathic pain associated with diabetic peripheral neuropathy
The new vaccines R&D center in Maryland will be the company’s third, in addition to those in Rixensart, Belgium and Siena, Italy. It will expand the company’s efforts
The deal, which includes up to $26m option premium and R&D funding, grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of Phase
The ANDA product is a generic version of Gilead Sciences’ Letairis, which is designed to treat patients with pulmonary arterial hypertension (PAH). On 01 April 2015, Gilead and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.